PERINDOPRIL IMPROVE ANTIRECURRENT EFFICACY OF SOTALOL IN PATIENTS WITH PERSISTENT ATRIAL FIBRILLATION
Ninety-seven patients after cardioversion of persistent atrial fibrillation were randomly assigned to receive sotalol 80-160 mg/day (n=49) or sotalol and perindopril 4-8 mg/day (n=48) for 12 months. Recurrences of atrial fibrillation were cardioverted with propafenone and/or amiodarone. After 12 month sinus rhythm was registred in 77,6% and 93,8% (p<0,05) respectively. Our results support the hypothesis that renin-angiotensin system inhibition addition to the usual antiarrhythmic treatment reduces recurrence persistent atrial fibrillation in patients with structural heart disease.